Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 18Recruiting 10Unknown 8Withdrawn 3Not yet recruiting 3Terminated 2Active not recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1CNS 1

Conditions

Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Anorexia 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Olanzapine × Clear all
NCT04939090 2026-04-13

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Alliance for Clinical Trials in Oncology

Phase 3 Active not recruiting
227 enrolled
Other hematologic neoplasm

Anorexia, Hematologic Neoplasms

NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
11 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡